Allergan Inc. and Molecular Partners AG have added two further agreements to a year-long, pre-existing collaboration on a new drug for wet age-related macular degeneration (AMD) that could lead to the fledgling Swiss biotech receiving up to $1.4 billion in development, regulatory and milestone payments, as well as tiered royalties into low double-digits on future product sales.
Back in May 2011, Molecular Partners out-licensed its lead Phase IIa "DARPin" vascular endothelial growth factor (VEGF) antagonist, MP0112, to Allergan in ophthalmic indications for an upfront of $45 million and up to $375 million in milestones and royalties Also see "Allergan Licenses Molecular Partners' Anti-VEGF